Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 113

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 113
---
384  $(52,508) $(227) $652 

     Additional     Accumulated Other       Common stock  Paid-in  Accumulated  Comprehensive      Shares  Amount  Capital  Deficit  Loss  Total                    Balance, December 31, 2023  3,189  $3  $52,262  $(40,310) $(203) $11,752                          Common shares issued for cash  39   -   55   -   -   55 Stock based compensation  -   -   213   -   -   213 Net loss for the period  -   -   -   (2,483)  -   (2,483)Balance, March 31, 2024  3,228  $3  $52,530  $(42,793) $(203) $9,537 

 5Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

   Three months ended    March 31,    2025  2024        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(2,372) $(2,483)Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation  192   213 Net change in fair value of trading marketable securities  -   (106)Non-cash lease expense  8   8 Changes in operating assets and liabilities:        Prepaid expenses and other current assets  9   5 Deferred offering costs  (424)  - Accounts payable and accrued liabilities  800   (624)Accounts payable - related parties  (38)  53 Advances from investors  236   - Fixed cash payments related to operating leases  (8)  (8)Net cash used in operating activities  (1,597)  (2,942)         CASH FLOWS FROM INVESTING ACTIVITIES        Investment in trading marketable securities  -   (481)Proceed